Head of Privacy Analytics
DIA’s Real World Evidence Conference
Date of Event: November 9, 2020
Location: Virtual Event
This conference will explore new and innovative applications of RWE, and deliver cutting-edge insights in how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.
Panel: Be a Change Agent, Not a Secret Agent
Monday, November 9th from 11:45 am to 12:15 pm ET
Presenters: Sarah Lyons, General Manager, Privacy Analytics and Tom Baker, VP Consulting, Europe, Middle East, Africa (EMEA), IQVIA
As the healthcare industry evolves into an ecosystem of data-rich, digitally enabled stakeholders, drug manufacturers are losing their informational advantage in the value chain.
To stay vital, sponsors are beginning to embrace an operating model based on collaboration, openness, and trust, with many moving toward actively sharing sensitive health data with partners.
In this panel, we’ll explore the implications of this new ecosystem, focusing on the data platform as a launchpad for innovation that benefits everyone and advances patient health.
Event registration is now closed.
Sarah helps Privacy Analytics’ clients earn trust and execute on their use priorities. Her career has often involved developing and implementing innovative risk assessment methodologies for governments and Fortune 500 companies. She has worked with decision makers at the highest level to identify and address financial, political and/or reputational risk before any harm could be done to the organization. Her previous roles include Partner and National Privacy Services Leader at MNP LLP, COO of A Hundred Answers Inc., and IT Risk Advisory Practice Lead for Ernst & Young Ottawa.
Head of Privacy Analytics
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to ensure the primary market research process was fully compliant with internal policies and regulations such as GDPR.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.